Physician profile
Katy Jones
NPI 1982837977
$2,748.20
in general payments reported to CMS, 2019-2025
27 companies · $474 in 2025
The $474 reported for 2025 was more than what 85% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $618 · 2022: $674 · 2023: $767 · 2024: $213 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.46 |
| Education | $113.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.59 | 2021-2025 | |
| Astellas Pharma US INC | $341.50 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $329.38 | 2022-2025 | |
| Janssen Biotech, INC. | $275.41 | 2023-2025 | Tremfya, Simponi Aria |
| Aspira Women'S Health INC | $201.70 | 2021-2022 | |
| Millicent US INC | $89.68 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Hikma Pharmaceuticals USA | $88.73 | 2021-2022 | |
| Avion Pharmaceuticals | $50.64 | 2021-2023 | Balcoltra |
| Organon LLC | $49.48 | 2022-2023 | Nexplanon |
| Pfizer INC. | $47.51 | 2021 | |
| Pharmacosmos Therapeutics INC. | $46.92 | 2023-2024 | Monoferric |
| Scynexis, INC. | $43.48 | 2022 | |
| Abiomed | $37.56 | 2025 | |
| Therapeuticsmd, INC. | $35.82 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $33.00 | 2023 | Iovera, Exparel, Zilretta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.31 | 2024-2025 | Actemra |
| Sumitomo Pharma America, INC. | $26.74 | 2025 | Myfembree |
| Hologic Sales and Service, LLC | $25.65 | 2023 | Aptima |
| Invivyd INC | $20.56 | 2025 | Pemgarda |
| Renovia INC | $20.24 | 2021 | |
| Celltrion USA INC. | $19.97 | 2023 | Yuflyma |
| Novo Nordisk INC | $19.59 | 2022 | |
| Horizon Therapeutics Plc | $16.29 | 2022 | |
| Channel Medsystems, INC. | $16.03 | 2022 | |
| Exact Sciences Corporation | $13.93 | 2025 | Cologuard Collection Kit |
| Urovant Sciences INC | $13.58 | 2022 | |
| Virtus Pharmaceuticals LLC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.